1. Adamas Pharmaceuticals Presents, 2013. Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia. In: Proceedings of the World Parkinson׳s Congress. Available from: 〈http://www.prnewswire.com/news-releases/adamas-pharmaceuticals-presents-positive-clinical-data-for-ads-5102-a-treatment-for-levodopa-induced-dyskinesia-at-the-world-parkinsons-congress-226143931.html〉 (accessed 20.02.14.).
2. Addex Reports Positive, 2012. Addex Reports Positive Top Line Phase IIa Data for Dipraglurant in Parkinson׳s Disease Levodopa-Induced Dyskinesia (PD-LID). Available from: 〈http://www.addextherapeutics.com/investors/press-releases/news-details/?tx_ttnews[tt_news]%20=198&cHash=f988c9505eb3a270be64f5669486042b〉. (accessed 02.02.14.).
3. The functional anatomy of basal ganglia disorders;Albin;Trends Neurosci.,1989
4. Dopaminergic agonists in Parkinson׳s disease;Alonso Cánovas;Neurologia,2014
5. COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson׳s disease (PD): relevance for motor and non-motor features;Antonini;Neuropsychiatr. Dis. Treat.,2008